Research Article
Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment
Figure 3
Subfoveal choroidal thickness (SFCT) changes after spironolactone treatment. The mean SFCT was significantly decreased after spironolactone treatment (406.06 ± 47.08 μm versus 368.94 ± 54.29 μm, ).